Dose dependent nanoparticle albumin bound paclitaxel + pembrolizumab alters the immune micro environment in a esophageal homograft mouse model

Esophageal cancer has remained a therapeutic challenge despite the advancements in targeted therapy and immunotherapy. This study investigated the mechanism by which neoadjuvant pembrolizumab combined with carboplatin and varying dosages of albumin-bound paclitaxel (ABP) regulates immune microenvironment in esophageal cancer. In vivo, a homograft mouse model was constructed. Both combined treatment groups displayed considerably decreased tumor volume (P